In September 2023, the US Food and Drug Administration approved momelotinib for the treatment of myelofibrosis (MF) with anemia, marking the fourth US regulatory approval of a Janus kinase inhibitor for MF. A positive opinion from the European Medicines Agency followed in November 2023. Momelotinib’s ability to address splenomegaly, symptoms, and anemia, including in patients with thrombocytopenia (with platelet counts of ≥25 × 10/L), the ease of switching from ruxolitinib, and good tolerability uniquely position it to substantially impact the MF treatment landscape.

中文翻译：

---

莫洛替尼用于治疗骨髓纤维化


2023年9月，美国食品和药物管理局批准莫莫替尼用于治疗伴有贫血的骨髓纤维化（MF），这是美国监管机构第四次批准Janus激酶抑制剂治疗MF。随后，欧洲药品管理局于 2023 年 11 月发表了积极意见。 Momelotinib 能够解决脾肿大、症状和贫血问题，包括血小板减少症患者（血小板计数≥25 × 10/L）、从鲁索替尼转换的容易性以及良好的耐受性使其能够对 MF 治疗前景产生重大影响。